News

Medical Xpress7y
Researchers map intricacies of lung cancer in one of their own - Medical Xpress
When James Spudich was diagnosed with lung cancer, researchers had a rare, and unexpected, opportunity to study healthy and diseased human tissue at an unprecedented level of detail.
WREG10mon
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - WREG.com
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer News provided by ArriVent BioPharma ...
Proof-of-concept study dissolves clusters of breast cancer cells to prevent metastases - MSN
More information: Christian Kurzeder et al, Digoxin for reduction of circulating tumor cell cluster size in metastatic breast ...
ascopubs.org1y
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) | JCO Precision Oncology - ASCO Publications
Lung-MAP, Lung Cancer Master Protocol; NSCLC, non–small-cell lung cancer. Discussion In this study, we found that a biomarker-driven master protocol for NSCLC improved access to novel therapeutics for ...
Yahoo3y
Achievers: Researcher earns grant to study drug delivery concept for lung cancer - Yahoo
An OU Health Stephenson Cancer Center researcher has earned a federal grant to study a new drug delivery concept for lung cancer.
The Electric14d
Great Falls Hospital adds new robot in effort to catch, treat lung cancer earlier
Lung cancer leading cause of cancer-related deaths worldwide. In U.S., the five-year survival rate for all stages of non-small cell lung cancer, the most common form, is only 28 percent, compared to ...
FiercePharma9y
Proof-of-concept study of fruquintinib in non-small cell lung cancer triggers milestone payment
London: Friday, 23 October 2015: Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, is set to receive a US ...
Oklahoma's News10mon
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer News provided by ArriVent BioPharma ...
ascopubs.org1y
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) | JCO Precision Oncology - ASCO Publications
Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared ...
FOX31 Denver10mon
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - FOX31 Denver
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer News provided by ArriVent BioPharma ...
Nasdaq10mon
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - Nasdaq
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer Published Aug 12, 2024 8:00am EDT ...